

Electronic Filing System (EFS) Data
Electronic Patent Application Submission
USPTO Use Only

EFS ID: 14247
Application ID: 10063046
Title of Invention: Peptide for Regulation of
Urokinase Plasminogen Activator
and Method of Optimizing
Therapeutic Efficacy
First Named Inventor: Abd. Al-Roof Higazi
Domestic/Foreign Application: Domestic Application
Filing Date: null
Effective Receipt Date: 2002-03-14
Submission Type: Utility Patent Filing
Filing Type: new-utility
Confirmation Number: 0
Attorney Docket Number: 143.006
Digital Certificate Holder: cn=Rashida A. Karmali, ou=Registered Attorneys, ou=Patent and
Trademark Office, ou=Department of Commerce, o=U.S.
Government, c=US
Certificate Message Digest: Nc772qH3UX2ujwqxpV56ig==
Total Fees Authorized: \$454.0
Payment Category: CC - Credit Card
Credit Card Number: *****1008
Expiration Date: 01312005
Card Holder Name: Rashida A. Karmali Esq.
RAM User ID: EFSPROD
RAM Accounting Date: 2002-03-14
RAM Sequence Number: 420032
RAM Payment Status: RAM success
Postal Code: 10011



TRANSMITTAL FORM


Electronic Version 1.0.3

Stylesheet Version: 1.0

Submission Type: Utility Patent
Filing

Attorney Docket
Number:

143.006



Peptide for Regulation of Urokinase Plasminogen Activator and Method of Optimizing Therapeutic Efficacy

First Named Inventor: Dr. Abd. Al-Roof Higazi

SUBMITTED BY

Name: Rashida A. Karmali

Registration Number: 43,705

Electronic Signature Mark: Rashida
A. Karmali

Date Signed: 20020314

I certify that the use of this system is for OFFICIAL correspondence between patent applicants or their representatives and the USPTO. Fraudulent or other use besides the filing of official correspondence by authorized parties is strictly prohibited, and subject to a fine and/or imprisonment under applicable law.

I, the undersigned, certify that I have viewed a display of document(s) being electronically submitted to the United States Patent and Trademark Office, using either the USPTO provided style sheet or software, and that this is the document(s) I intend for initiation or further prosecution of a patent application noted in the submission. This document(s) will become part of the official electronic record at the USPTO.

Attached Files:

declaration	declaration1.tif
declaration	declaration2.tif

declaration	declaration3.tif
declaration	Assignment1.tif
declaration	Assignment2.tif
fee-transmittal	Higaziffee.xml
bibd-transmittal	Higaziapds.xml
specification	Peptide.xml

Attached Image File(s):

declaration1.tif
declaration2.tif
declaration3.tif
Assignment1.tif
Assignment2.tif

Comments:

[illegible]

Express Mail Label No.

Page

Docket No.

Declaration and Power of Attorney For Patent Application

English Language Declaration

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

Use of Cross-Linked, Covalently Bound Urokinase Plasminogen Activator (scuPA)-Urokinase Plasminogen Activator Receptor (suPAR) Complex As A Fibrinolytic Agent

the specification of which

(check one)

☐ is attached hereto.

☐ was filed on _____ as United States Application No. or PCT International Application Number _____ and was amended on _____

(if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Priority Not Claimed

I hereby claim the benefit under 35 U.S.C. Section 119(e) of any United States provisional application(s) listed below:

(Application Serial No.)

(Filing Date)

(Application Serial No.)

(Filing Date)

(Application Serial No.)

(Filing Date)

I hereby claim the benefit under 35 U. S. C. Section 120 of any United States application(s), or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. Section 112, I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, C. F. R., Section 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application:

(Application Serial No.)

(Filing Date)

(Status)
(patented, pending, abandoned)

(Application Serial No.)

(Filing Date)

(Status)
(patented, pending, abandoned)

(Application Serial No.)

(Filing Date)

(Status)
(patented, pending, abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. (List name and registration number)

Rashida A. Karmali, Esq.

Reg. No. 43,705

Send Correspondence to: Rashida A. Karmali, Esq.
230 Park Avenue, Suite 1000
New York, New York 10169

Direct Telephone Calls to: (name and telephone number) (212) 808-6589

Full name of sole or first inventor	Abd. Al-Roof HIGAZI	
Sole or first inventor's signature	<u>Higazi</u>	Date <u>2-6-01</u>
Residence	Neve Shalom Street 1, Neve Shalom 99761 M.P., Shimon, Israel	
Citizenship	[Israel]	
Post Office Address	Same as above	

Full name of second inventor, if any	
Second inventor's signature	Date
Residence	
Citizenship	
Post Office Address	

Assignment of Rights in Invention (Sole inventor; single assignee)		Docket No. 143.004
Inventor	Residence of Inventor	
Abd. Al-Roof HIGAZI	Neve Shalom, 99761 D.N. Shimshon, Israel	
Assignee	Residence or Principal Place of Business of Assign	
Hadasit Medical Research Services & Development Company Ltd.	P.O. Box 1200 Jerusalem 91120 Israel	

Whereas, I, the above-identified Inventor, have invented certain new and useful improvements in:

Use of Cross-Linked, Covalently Bound Urokinase Plasminogen Activator (scuPA)-Urokinase Plasminogen Activator Receptor (suPAR) Complex As A Fibrinolytic Agent

(hereinafter referred to as "Invention") for which I am making application for Letters Patent in the United States of Ameri

And, whereas I desire to assign a 100% undivided interest in said Invention, said application disclosing the Inve and any Letters Patent which may be granted therefor to the above-identified Assignee, and whereas said Assignee is desir acquiring the entire right, title and interest in the same;

*Now, this indenture witnesseth, that for the sum of . one dollars
, and other good and valuable consideration, the receipt whereof is hereby acknowledged;*

I hereby assign, sell and transfer a 100% undivided interest in said invention, said application, including any divi continuations, and continuations-in-part thereof, and in and to any and all Letters Patent of the United States, and cou foreign thereto, which may be granted for said Invention, and in and to any and all priority rights, Convention rights, and benefits accruing or to accrue to me with respect to the filing of applications for patents or securing of patents in the U States and countries foreign thereto, unto said Assignee;

And I hereby authorize and request the Commissioner of Patents and Trademarks to issue said United States L Patent to said Assignee, as assignee of the whole right, title and interest thereto;

And I further agree to execute all necessary and lawful future documents, including assignments in favor of Assi or its designees as Assignee or its Assignees may from time-to-time present to me in order to perfect title in said Inven modifications, and improvements in said Invention, applications and Letters Patent of the United States and countries fo thereto;

27-JUN-01 WED 11:56

Clin Biochem, Hadassah

FAX NO. -972 2 3435 778

P. 1

JUN-25-2001 10:16 AM

P. 03

Assignment of Rights in Invention (Sole inventor; single assignee)		Docket No.
Inventor	Residence of Inventor	
Abd. Al-Roof HIGAZI	Neve Shalom Street 1 Neve Shalom 99761 M.P. Shimshon, Israel	
Assignee	Residence or Principal Place of Business of Assignee	
Hadassah Medical Research Services & Development Company Ltd.	P.O. Box 12000 91120 Jerusalem Israel	
<p>And I further agree to sign and properly execute such necessary and lawful papers for application for foreign patents, for filing divisions, continuations and continuations-in-part of said application for patent, and/or, for obtaining any extension or renewal of any Letters Patent which may be granted for my aforesaid invention, as the Assignee thereof shall hereafter require and prepare at its own expense.</p> <p>Executed this 27 day of 6, in the year 2001</p> <p>at _____</p> <p>State of _____</p> <p>County of _____</p> <p>Before me personally appeared Abd. Al-Roof HIGAZI who acknowledged the foregoing instrument to be a free act and deed and also represented that he or she is authorized to execute the same this _____ day of _____, in the year _____</p> <p>_____ (Notary Public)</p>		

FEE TRANSMITTAL

Electronic Version 1.1.0

Stylesheet Version: 1.0

Patent fees are subject to annual revisions on or about October 1st of each year.

Small Entity

Small Business Concern

TOTAL FEES AUTHORIZED: \$ 454

BANK (CREDIT) CARD INFORMATION:

Credit Card Number: 1008
Expiration Date: 20050131
Authorized Name: Rashida A. Karmali Esq.
Billing Address: 10011

BASIC FILING FEE

Fee Description	Fee Code	Fee Paid
Utility Filing Fee	201	\$ 370

Subtotal For Basic Filing Fee: \$ 370

EXTRA CLAIM FEES

	Fee Code	Fee	Extra Claims	Fee Paid
Total Claims: 10	203	\$ 9	0	\$ 0
Independent Claims: 5	202	\$ 42	2	\$ 84

Subtotal For Extra Claims Fees: \$ 84